Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

TECAN GROUP LTD.

Tecan is a provider of automated laboratory instruments and solutions for people working in clinical diagnostics, bas... read more Featured Products: More products

Download Mobile App




Two Chikungunya Virus IgM Enzyme-Linked Immunoassays Evaluated

By LabMedica International staff writers
Posted on 11 Feb 2020
Chikungunya virus (CHIKV) is an alphavirus transmitted by Aedes (Stegomyia) spp. mosquitoes. Transmission was initially restricted to small outbreaks and sporadic cases in Africa and Asia, but since early 2000s the virus has caused large outbreaks in India and Southeast Asia.

Acute clinical manifestations associated with CHIKV infections are non-specific, usually including fever, rash, and arthralgia, the latter being the most prominent symptom that may last for months or years, causing chronic disabilities. In areas where other arboviruses with similar clinical manifestations co-circulate laboratory diagnostic tools that distinguish CHIKV infections from them are urgently needed.

Scientists from the Fundação Oswaldo Cruz (Salvador, Brazil) enrolled 372 patients attending a public emergency health unit in an acute febrile illness (AFI) enhanced surveillance study and blood samples were drawn for arboviral diagnosis. All acute-phase sera, which had not been previously thawed, were submitted to RNA extraction and tested by reverse-transcription polymerase chain reaction (RT-PCR) for Dengue (DENV), Zika (ZIKV), and CHIKV.

The team tested the acute- and paired convalescent-phase sera available from all the CHIKV, DENV, and ZIKV RT-PCR-positive patients enrolled during surveillance with both the CHIKjj Detect IgM-capture ELISA kit (Inbios International, Inc., Seattle, WA, USA) and the Anti-Chikungunya virus ELISA (IgM) Test (Euroimmun, Luebeck, Germany). They also applied the Inbios and the Euroimmun CHIKV IgM ELISA tests to the acute- and paired convalescent-phase sera from 175 patients randomly selected from those with negative RT-PCR results (for all three arboviruses) and with paired sera available. The ELISA reading was performed by automated microplate reader at 450 nm (TECAN, Männedorf, Switzerland).

The scientists reported that the Inbios and Euroimmun tests’ sensitivities for acute samples were 4.0% and 10.3%, while for convalescent samples they were 92.4% and 96.9%, respectively. Overall, Inbios IgM ELISA specificities for acute and convalescent samples were 97.7% and 90.5%, respectively, and Euroimmun specificities were 88.5% and 83.9%, respectively.

The authors concluded that both tests presented high sensitivity for convalescent samples. However, the Euroimmun test returned more equivocal results and presented a slightly lower specificity, which might result in a higher rate of false positives if the test is used in scenarios of low CHIKV transmission, when the chance of CHIKV infection is lower. The study was published in the February, 2020 issue of International Journal of Infectious Diseases.


Related Links:
Fundação Oswaldo Cruz
Inbios International
Euroimmun
TECAN



New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mumps Virus Test
ZEUS ELISA Mumps IgG Test System
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.